Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML

Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML

Abstract Background CPX-351 (United States: Vyxeos®; Europe: Vyxeos® Liposomal), a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio, is approved by the US FDA and the EMA for the treatment of adults with newly diagnosed therapy-related acute myeloid l...

Full description

Bibliographic Details
Main Authors: Jorge E. Cortes, Tara L. Lin, Geoffrey L. Uy, Robert J. Ryan, Stefan Faderl, Jeffrey E. Lancet
Format: Article
Language:English
Published: BMC 2021-07-01
Series:Journal of Hematology & Oncology
Subjects:
Acute myeloid leukemia
Chemotherapy
Relapse
Survival
Toxicity
Quality-of-life
Online Access:https://doi.org/10.1186/s13045-021-01119-w

Similar Items

Similar Items